Spark Therapeutics

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards...
  3. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  4. Resolving capping issues in tablet manufacturing Natoli explores the various causes of capping and the methods to prevent it
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Media

Licensing and supply agreement for voretigene neparvovec outside the US

Spark Therapeutics announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialise investigational voretigene neparvovec outside the US, while Spark Therapeutics will continue to exclusively commercialise Luxturna (voretigene neparvovec-ryzl) in the US
Recruitment

Spark Therapeutics announces addition to Board of Directors
Regulatory

Price tag of $850,000 set for Luxturna gene therapy

The US Food and Drug Administration approved Luxturna last month, a new gene therapy to treat children and adult patients with an inherited form of vision loss that may result in blindness but the price has only just be revealed
Research & Development

Pfizer expands rare disease research with establishment of gene therapy platform

Appoints Michael Linden to head its genetic research into rare diseases
Subscribe now